Document is current
Any future updates will be listed below
-
Authors
Jiang, Allen Y. https://orcid.org/0000-0002-9826-5976
Cristian, Ana
Brooks, Dominique L.
Feierman, Emily R. https://orcid.org/0000-0002-2133-5825
Chen, Paul Z. https://orcid.org/0000-0001-5261-1610
Whittaker, Madelynn N.
Pierce, Sarah E. https://orcid.org/0000-0002-9145-9559
Sakai, Holt A. https://orcid.org/0000-0002-9338-1484
Chen, Hongyu https://orcid.org/0000-0002-9496-8586
Liu, Dangliang https://orcid.org/0000-0001-6598-8871
Randolph, Peyton B. https://orcid.org/0000-0001-6385-364X
Li, Angus H. https://orcid.org/0000-0002-7330-465X
Hsu, Alvin https://orcid.org/0000-0003-4034-2788
Omo-Lamai, Serena O.
Tao, Y. Allen
Owusu-Amo, Benista
Wang, Xiao
Wang, Xiao
Musunuru, Kiran https://orcid.org/0000-0003-3298-0368
Liu, David R. https://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Bill and Melinda Gates Foundation (INV-056974;)
Howard Hughes Medical Institute (Liu)
- License Information
-
More Information
Article History
Received: 23 October 2025
Accepted: 12 May 2026
First Online: 15 June 2026
Competing interests
: A.Y.J., A.C. and D.R.L. have filed patent applications on this work through the Broad Institute. K.M. is an advisor to and holds equity in Verve Therapeutics and Variant Bio, is an advisor to LEXEO Therapeutics and Capstan Therapeutics and receives research funding from Nava Therapeutics and Beam Therapeutics. D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants and nChroma Bio, companies that use or deliver genome editing or epigenome engineering agents. X.W. (MIT) is a consultant, equity holder and scientific cofounder of Stellaromics and Convergence Bio. The other authors declare no competing interests.
